Form 8-K - Current report:
SEC Accession No. 0001641172-25-017478
Filing Date
2025-07-02
Accepted
2025-07-02 09:00:41
Documents
14
Period of Report
2025-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44732
2 EX-4.1 ex4-1.htm EX-4.1 89115
3 EX-4.2 ex4-2.htm EX-4.2 138978
  Complete submission text file 0001641172-25-017478.txt   492788

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE sonn-20250630.xsd EX-101.SCH 3017
5 XBRL LABEL FILE sonn-20250630_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE sonn-20250630_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3740
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Filer) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-35570 | Film No.: 251098529
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)